SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-129321
Filing Date
2019-04-30
Accepted
2019-04-30 16:10:55
Documents
5
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A d731105ddefa14a.htm DEFA14A 19413
2 GRAPHIC g731105dsp001.jpg GRAPHIC 146350
3 GRAPHIC g731105dsp002.jpg GRAPHIC 196259
4 GRAPHIC g731105dsp003.jpg GRAPHIC 88090
5 GRAPHIC g731105dsp004.jpg GRAPHIC 61750
  Complete submission text file 0001193125-19-129321.txt   693122
Mailing Address P. O. BOX # 110341 RESEARCH TRIANGLE PARK NC 27709
Business Address 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38096 | Film No.: 19781796
SIC: 2834 Pharmaceutical Preparations